Journal of Clinical Oncology, Vol 16, 1380-1387, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer

C Lindley, S Vasa, WT Sawyer and EP Winer
School of Pharmacy and Medicine, University of North Carolina at Chapel Hill, 27599-7360, USA. CLindley.Pharm@mhs.unc.edu

PURPOSE: To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS: Eighty- six patients who had completed systemic adjuvant therapy for early- stage breast cancer between 1988 and 1991 were surveyed by written questionnaire and telephone interview. Sociodemographic information was obtained for each patient, and patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), the Medical Outcomes Study (MOS) Short Form 36 (SF-36), a series of questions regarding sexual function, and a survey about preferences for adjuvant therapy in relation to possible benefit. RESULTS: The mean FLIC score among all patients was 138.3 (+/- 12.2), which suggests a high level of QOL. The reported frequency of moderate to severe symptoms was generally low (ie, < 15%), with fatigue (31.4%), insomnia (23.3%), and local numbness at the site of surgery (22.1%) occurring with greatest frequency. Patients reported a wide range of sexual difficulties. Preference assessment showed that more than 65% of patients were willing to undergo 6 months of chemotherapy for a 5% increase in likelihood of cancer cure. CONCLUSION: Self-rated QOL in breast cancer patients 2 to 5 years following adjuvant therapy was generally favorable. Less than one third of patients reported moderate to severe symptoms. Selected aspects of sexual function appeared to be compromised. The majority of patients indicated a willingness to accept 6 months of chemotherapy for small to modest potential benefit.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. R. Bossema, C. A. M. Marijnen, M. C. M. Baas-Thijssen, C. J. H. van de Velde, and A. M. Stiggelbout Evaluation of the Treatment Tradeoff Method in Rectal Cancer Patients: Is Surgery Preference Related to Outcome Utilities? Med Decis Making, November 1, 2008; 28(6): 888 - 898. [Abstract] [PDF]

				R. S. Punglia, M. Morrow, E. P. Winer, and J. R. Harris Local Therapy and Survival in Breast Cancer N. Engl. J. Med., June 7, 2007; 356(23): 2399 - 2405. [Full Text] [PDF]

				K. H. Schmitz, A. R. Cappola, C. T. Stricker, C. Sweeney, and S. A. Norman The Intersection of Cancer and Aging: Establishing the Need for Breast Cancer Rehabilitation Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 866 - 872. [Abstract] [Full Text] [PDF]

				J. A. Roscoe, M. E. Kaufman, S. E. Matteson-Rusby, O. G. Palesh, J. L. Ryan, S. Kohli, M. L. Perlis, and G. R. Morrow Cancer-Related Fatigue and Sleep Disorders Oncologist, May 1, 2007; 12(suppl_1): 35 - 42. [Abstract] [Full Text] [PDF]

				S. R. Burwell, L. D. Case, C. Kaelin, and N. E. Avis Sexual Problems in Younger Women After Breast Cancer Surgery J. Clin. Oncol., June 20, 2006; 24(18): 2815 - 2821. [Abstract] [Full Text] [PDF]

				D. J. Weschules, T. Maxwell, J. Reifsnyder, and C. H. Knowlton Are newer, more expensive pharmacotherapy options associated with superior symptom control compared to less costly agents used in a collaborative practice setting? American Journal of Hospice and Palliative Medicine, March 1, 2006; 23(2): 135 - 149. [Abstract] [PDF]

				P. Nieboer, C. Buijs, S. Rodenhuis, C. Seynaeve, L. V.A.M. Beex, E. van der Wall, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, et al. Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study J. Clin. Oncol., November 20, 2005; 23(33): 8296 - 8304. [Abstract] [Full Text] [PDF]

				J. E. Bower Prevalence and Causes of Fatigue After Cancer Treatment: The Next Generation of Research J. Clin. Oncol., November 20, 2005; 23(33): 8280 - 8282. [Full Text] [PDF]

				C. C. Gotay, J. Lipscomb, and C. F. Snyder Reflections on Findings of the Cancer Outcomes Measurement Working Group: Moving to the Next Phase J Natl Cancer Inst, November 2, 2005; 97(21): 1568 - 1574. [Abstract] [Full Text] [PDF]

				V. M. Duric, M. R. Stockler, S. Heritier, F. Boyle, J. Beith, A. Sullivan, N. Wilcken, A. S. Coates, and R. J. Simes Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann. Onc., November 1, 2005; 16(11): 1786 - 1794. [Abstract] [Full Text] [PDF]

				S.J.T. Jansen, W. Otten, M.C.M. Baas-Thijssen, C.J.H. van de Velde, J.W.R. Nortier, and A.M. Stiggelbout Explaining Differences in Attitude Toward Adjuvant Chemotherapy Between Experienced and Inexperienced Breast Cancer Patients J. Clin. Oncol., September 20, 2005; 23(27): 6623 - 6630. [Abstract] [Full Text] [PDF]

				R. W Wilson, L. M Hutson, and D. VanStry Comparison of 2 Quality-of-Life Questionnaires in Women Treated for Breast Cancer: The RAND 36-Item Health Survey and the Functional Living Index-Cancer Physical Therapy, September 1, 2005; 85(9): 851 - 860. [Abstract] [Full Text] [PDF]

				R. Knols, N. K. Aaronson, D. Uebelhart, J. Fransen, and G. Aufdemkampe Physical Exercise in Cancer Patients During and After Medical Treatment: A Systematic Review of Randomized and Controlled Clinical Trials J. Clin. Oncol., June 1, 2005; 23(16): 3830 - 3842. [Abstract] [Full Text] [PDF]

				J. E. Bower, P. A. Ganz, and N. Aziz Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue Psychosom Med, March 1, 2005; 67(2): 277 - 280. [Abstract] [Full Text] [PDF]

				J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 8 - 44. [Abstract] [Full Text] [PDF]

				S. J.T. Jansen, W. Otten, and A. M. Stiggelbout Review of Determinants of Patients' Preferences for Adjuvant Therapy in Cancer J. Clin. Oncol., August 1, 2004; 22(15): 3181 - 3190. [Abstract] [Full Text] [PDF]

				P. A. Davol, R. Bagdasaryan, G. J. Elfenbein, A. L. Maizel, and A. R. Frackelton Jr. Shc Proteins Are Strong, Independent Prognostic Markers for Both Node-Negative and Node-Positive Primary Breast Cancer Cancer Res., October 15, 2003; 63(20): 6772 - 6783. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365. [Abstract] [Full Text] [PDF]

				J. E. Bower, P. A. Ganz, N. Aziz, J. L. Fahey, and S. W. Cole T-Cell Homeostasis in Breast Cancer Survivors With Persistent Fatigue J Natl Cancer Inst, August 6, 2003; 95(15): 1165 - 1168. [Abstract] [Full Text] [PDF]

				K.-A. Phillips and J. Bernhard Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions J Natl Cancer Inst, February 5, 2003; 95(3): 190 - 197. [Abstract] [Full Text] [PDF]

				D. Miles, G. von Minckwitz, and A. D. Seidman Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer Oncologist, December 1, 2002; 7(90006): 13 - 19. [Abstract] [Full Text] [PDF]

				J. E. Bower, P. A. Ganz, N. Aziz, and J. L. Fahey Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors Psychosom Med, July 1, 2002; 64(4): 604 - 611. [Abstract] [Full Text] [PDF]

				A. H. Partridge, H. J. Burstein, and E. P. Winer Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 135 - 142. [Abstract] [Full Text] [PDF]

				R. J. Simes and A. S. Coates Patient Preferences for Adjuvant Chemotherapy of Early Breast Cancer: How Much Benefit Is Needed? J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 146 - 152. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J. Clin. Oncol., September 15, 2001; 19(18): 3817 - 3827. [Full Text] [PDF]

				S. J. T. Jansen, J. Kievit, M. A. Nooij, and A. M. Stiggelbout Stability of Patients' Preferences for Chemotherapy: The Impact of Experience Med Decis Making, August 1, 2001; 21(4): 295 - 306. [Abstract] [PDF]

				A. B. Kornblith Does Palliative Care Palliate? J. Clin. Oncol., April 15, 2001; 19(8): 2111 - 2113. [Full Text] [PDF]

				J. Savard and C. M. Morin Insomnia in the Context of Cancer: A Review of a Neglected Problem J. Clin. Oncol., February 1, 2001; 19(3): 895 - 908. [Abstract] [Full Text] [PDF]

				A. M. Stiggelbout and J. C.J.M. de Haes Patient Preference for Cancer Therapy: An Overview of Measurement Approaches J. Clin. Oncol., January 1, 2001; 19(1): 220 - 230. [Abstract] [Full Text] [PDF]

				J. E. Bower, P. A. Ganz, K. A. Desmond, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life J. Clin. Oncol., February 14, 2000; 18(4): 743 - 743. [Abstract] [Full Text] [PDF]

				J. E. Mortimer, L. Boucher, J. Baty, D. L. Knapp, E. Ryan, and J. H. Rowland Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1488 - 1488. [Abstract] [Full Text] [PDF]

				C. K. Daugherty Impact of Therapeutic Research on Informed Consent and the Ethics of Clinical Trials: A Medical Oncology Perspective J. Clin. Oncol., May 1, 1999; 17(5): 1601 - 1601. [Abstract] [Full Text] [PDF]